RAMUCIRUMAB PLUS ATEZOLIZUMAB IN PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH IMMUNE CHECKPOINT BLOCKADE